Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2275)

[medding]

OK. Habe die Meldungen auf Finanznet doch gefunden. Sieht nicht gut aus.

[medding]

Weis irgendjemand was bei Novavax los ist.
Habe keine neg. Meldungen im I-net gefunden.

[occitanie]

Salut

http://www.cnbc.com/id/33721487/for/cnbc/

A bientot
OC

[occitanie]

Sorry

http://www.streetinsider.com/New+Coverage/Merriman+Curhan+St…

A Bientot
OC

[occitanie]

Salut

http://www.streetinsider.com/New+Coverag...

A bientot
OC

[occitanie]

Saut
Interessiert sowieso Keine
http://news.yahoo.com/s/afp/20091102/hl_afp/healthfluusvacci…
A Bientot
OC

[occitanie]

Abschied
OC

[medding]

Kontakt:
Tricia Richardson Tricia Richardson
Senior Manager, Investor Relations Senior Manager, Investor Relations
Novavax, Inc. Novavax, Inc.
240-268-2031 240-268-2031
Novavax Announces Release Date of 2009 Third Quarter, Novavax Announces Release Date of Third Quarter 2009,
Financial Results and Investor Conference Call Financial Results and Investor Conference Call
ROCKVILLE, MD, (Oct 30, 2009) /PRNewswire-FirstCall/ - Novavax, Inc. (Nasdaq: NVAX) today announced that Rockville, MD, (30. Oktober 2009) / PRNewswire / - Novavax, Inc. (Nasdaq: NVAX) gab heute bekannt, dass
it will report its 2009 third quarter financial results in a press release to be issued after 8:00 am local time on Friday, es wird seinen Bericht dritten Quartal 2009 die finanziellen Ergebnisse in einer Pressemitteilung, die nach 8:00 ausgestellt Uhr Ortszeit am Freitag,
November 6, 2009. 6. November 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 am Das Unternehmen wird eine Konferenzschaltung für Investoren auf die finanziellen Ergebnisse zu diskutieren, 10:00 Uhr
local time on Friday, November 6, 2009. Ortszeit am Freitag, 6. November 2009. The call will be hosted by Novavax President and Chief Executive Officer Die Telefonkonferenz wird von Novavax President und Chief Executive Officer
Dr. Rahul Singhvi and other members of senior management. Dr. Rahul Singhvi und andere Mitglieder der Unternehmensleitung. A question and answer session will follow the Ein Frage-Antwort-Sitzung werden die folgen
financial results overview. Überblick über die finanziellen Ergebnisse. The dial-in number for the conference call is 1 [phone] (International: 1 (703) Die Einwahlnummer für die Telefonkonferenz ist 1 [phone] (International: 1 (703)
639-1367). 639-1367).
A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Ein Live-Audio-Webcast der Telefonkonferenz wird auf www.novavax.com unter Investoren verfügbar / Events. Please Bitte
connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software eine Verbindung zu dieser Website mindestens 15 Minuten vor der Telefonkonferenz, um genügend Zeit für eventuelle Software zu gewährleisten
download that may be needed to hear the webcast. download, die benötigt werden, können den Webcast zu hören. A replay of the webcast will be available on the website for 90 Eine Aufzeichnung des Webcasts wird auf der Website verfügbar für 90
days after the call and a replay of the conference call will also be available by telephone beginning November 6, Tage nach dem Aufruf und eine Aufzeichnung der Telefonkonferenz wird auch per Telefon ab 6. November zur Verfügung,
2009 at 1:00 pm through November 8, 2009 at 11:59 pm. 2009 at 1:00 pm durch 8. November 2009 um 11:59 Uhr. To access the replay, dial 1 [phone] and enter pass Um die Aufzeichnung zuzugreifen, wählen 1 [phone] und geben Sie den
code 1394584. Code 1394584

[occitanie]

Antwort auf Beitrag Nr.: 38.254.956 von occitanie am 26.10.09 17:48:17

Presentation Abstract

Session: 110-Late Breaker Posters
Saturday, Oct 31, 2009, 12:30 PM - 2:00 PM
Presentation: LB-13 - Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults
Location: Poster Hall A
Pres. Time: Saturday, Oct 31, 2009, 12:30 PM - 2:00 PM
Category: V. Virology including clinical and basic studies of viral infections, other than HIV, and hepatitis
Keywords: INFLUENZA VACCINE; CLINICAL TRIAL; ADULT IMMUNIZATION
Author(s): PENNY HEATON, MD1, MARIA ALLENDE, MD2, KATHY LENHARD, RN3, MIKE MASSARE, PhD3, MARK WOLFF, PhD3;
1NOVAVAX INC, Rockville, MD,2NOVAVAX Inc), Rockville, MD,3NOVAVAX Inc, Rockville, MD.

Abstract: Background:
Novel influenza vaccines grown in cell culture without dependence on eggs are needed to improve efficacy and timeliness of vaccine supply. Previously, a trivalent seasonal influenza (TSI) virus-like particle (VLP) vaccine against 2005-2006 strains was well tolerated and immunogenic in a phase 2 study. We report here results of a second phase 2 study of TSI VLP vaccine containing virus-like particles (VLPs) against the H1N1, H3N2, and B strains recommended for the 2008-2009 vaccine. Each VLP was composed of hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins produced in Spodoptera frugiperda (Sf9) insect cells transfected with baculoviruses.

Methods:
Subjects aged 18 to 49 years were randomly assigned in a blinded fashion to receive TSI VLP vaccine at 15 µg (N=85) or 60 µg (N=85) HA/strain or placebo (N=50). Safety follow-up included solicited events (SE), adverse events (AEs) and serious AEs (SAEs). Hemagglutination inhibition (HAI) titers against vaccine strains A/Brisbane/59/2007 (H1N1); A/Brisbane/10/2007 (H3N2); and B/Florida/4/2006; and against drifted strains were measured 3 weeks post-vaccination.

Results:
No vaccine-related SAEs were reported. Common SE included local pain and tenderness, myalgia, headache, and fever; overall rates for vaccine and placebo arms were comparable. Seroconversion (≥4-fold rise in HAI titer post-immunization) rates (95% CIs) post-vaccination for the 15 and 60 µg doses, respectively, were: H1N1 - 57% (44,68) and 66% (53,77); H3N2 - 86% (75,93) and 81% (69,89); B - 62% (50,74) and 67 (55,78). Seroprotection rates (HAI titers >1:40 post-vaccination) for the 15 and 60 µg doses, respectively, were 67% and 78% for H1N1; 91% and 94% for H3N2; and 84% and 88% for the B strain.

Conclusion:
The TSI VLP vaccine was well tolerated and immunogenic. HAI responses were robust and met the FDA criteria for licensure of influenza vaccines at the 60 µg dose for the H1N1 strain and at the 15 µg and 60 µg doses for the H3N2 and B strains. These results support continued development of the TSI VLP vaccine.

Disclosures: P. Heaton,
Novavax Role(s): Employee, Received: Salary.
M. Allende,
NOVAVAX Inc Role(s): Employee, Received: Salary.
K. Lenhard,
NOVAVAX Inc Role(s): Employee, Received: Salary.
M. Massare,
NOVAVAX Inc Role(s): Employee, Received: Salary.
M. Wolff,
NOVAVAX Inc Role(s): Independent Contractor, Received: Other Financial Benefit.
A Bientot
OC

[occitanie]

Bin Dabei